How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 601–700 of 1,024
Translation of rare disease research into orphan drug development: disease matters
Heemstra, H. E., van Weely, S., Büller, H. A., Leufkens, H. G. M., & de Vrueh, R. L. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.008 · Cited by 85
Cao, C., & Moult, J. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s4-s5 · Cited by 89
“Possible data related reasons for low overlap One possible cause of lower overlap is that in Drugbank, some drug targets do not have a known mechanism and are probably ‘predicted’ targets based on sequence similarity to other verified drug targets [7,8], and thus may be incorrect.”
BackgroundGarcia‐Marcos, M., Ghosh, P., Ear, J., & Farquhar, M. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045161 · Cited by 75
A Novel CMKLR1 Small Molecule Antagonist Suppresses CNS Autoimmune Inflammatory Disease
Graham, K. L., Zhang, J. V., Lewén, S., Burke, T. M., Dang, T., Zoudilova, M., Sobel, R. A., Butcher, E. C., & Zabel, B. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112925 · Cited by 82
“Therefore, MS treatments that inhibit CMKLR1, CCR2 or other candidate receptors as part of a ‘polypharmacologic’ approach may be more efficacious than targeting a single receptor [58].”
Diallinas, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00207 · Cited by 87
“For example, while G-protein-coupled receptors (GPCRs) represent more than one-quarter of drug targets, currently approved inhibitors of transporters are ten times less (Overington et al., 2006).”
BackgroundDigallate Dimers of (−)-Epigallocatechin Gallate Inactivate Herpes Simplex Virus
Isaacs, C. E., Xu, W., Merz, G., Hillier, S. L., Rohan, L. C., & Wen, G. Y. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05531-11 · Cited by 80
Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs
Lee, S. M., Booe, J. M., & Pioszak, A. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.013 · Cited by 92
“It is estimated that ~ 30% of drugs on the market target a GPCR and yet a relatively small number of GPCRs are currently targeted by marketed drugs (Overington et al., 2006).”
BackgroundEfremov, R. G., Gatsogiannis, C., & Raunser, S. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.05.007 · Cited by 89
Huber, T., Menon, S., & Sakmar, T. P. (2008) · Biochemistry · doi:10.1021/bi800891r · Cited by 76
“Clearly, monoaminergic receptors, which are targets for several major classes of cardiovascular and psychotropic drugs (77), will remain a central focus in pharmaceutical research and development (10, 18).”
BackgroundDurán, R. C., Wei, H., Kim, D. H., & Wu, J. Q. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12541 · Cited by 81
Protein Structure Prediction and Design in a Biologically Realistic Implicit Membrane
Alford, R. F., Fleming, P. J., Fleming, K. G., & Gray, J. J. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.03.006 · Cited by 79
“M 1⁄4 sinðqðzÞÞ cosðqðzÞÞ cosðqðzÞÞ sinðqðzÞÞ ; (2)”
BackgroundSubcellular Mass Spectrometry Imaging and Absolute Quantitative Analysis across Organelles
Thomen, A., Najafinobar, N., Penen, F., Kay, E., Upadhyay, P. P., Li, X., Phan, N. T. N., Malmberg, P., Klarqvist, M., Andersson, S., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09804 · Cited by 76
Ion channels as lipid sensors: from structures to mechanisms
Thompson, M. J., & Baenziger, J. E. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00693-3 · Cited by 78
Yue, Y., Wang, Z., Zhong, T., Guo, M., Huang, L., Yang, L., Kan, J., Zalán, Z., Hegyi, F., Takács, K., et al. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127253 · Cited by 86
Modern Technologies for Creating Synthetic Antibodies for Clinical Application
Deyev, S. M., & Lebedenko, E. N. (2009) · Acta Naturae · doi:10.32607/20758251-2009-1-1-32-50 · Cited by 86
Oldenkamp, R., Hoeks, S., Čengić, M., Barbarossa, V., Burns, E. E., Boxall, A. B. A., & Ragas, A. M. J. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b03862 · Cited by 77
Structure-Based Drug Design for G Protein-Coupled Receptors
Congreve, M., Dias, J. M., & Marshall, F. H. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00001-9 · Cited by 79
Kellenberger, E., Hofmann, A., & Quinn, R. J. (2011) · Natural Product Reports · doi:10.1039/c1np00026h · Cited by 85
Antibody informatics for drug discovery
Shirai, H., Prades, C., Vita, R., Marcatili, P., Popovic, B., Xu, J., Overington, J. P., Hirayama, K., Soga, S., Tsunoyama, K., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.07.006 · Cited by 75
Self-citationLaufer, S., Hauser, D. R. J., Domeyer, D. M., Kinkel, K., & Liedtke, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701529q · Cited by 73
G-Protein-Coupled Receptors in Adult Neurogenesis
Doze, V. A., & Perez, D. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004762 · Cited by 80
“Not surprisingly, GPCRs are important drug targets with at least 30% of all modern therapeutics acting at these receptors (Overington et al., 2006; Lagerström and Schiöth, 2008).”
BackgroundEvidence for a Transient Additional Ligand Binding Site in the TAS2R46 Bitter Taste Receptor
Sandal, M., Behrens, M., Brockhoff, A., Musiani, F., Giorgetti, A., Carloni, P., & Meyerhof, W. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00472 · Cited by 87
Bennett, K. A., Tehan, B. G., Lebon, G., Tate, C. G., Weir, M., Marshall, F. H., & Langmead, C. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084509 · Cited by 73
“GPCRs are important therapeutic targets; over 26% of all FDA-approved drugs act at rhodopsin-like GPCRs (Overington et al., 2006).”
BackgroundGuo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00025 · Cited by 86
Sensitivity in Binding Free Energies Due to Protein Reorganization
Lim, N. M., Wang, L., Abel, R., & Mobley, D. L. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00532 · Cited by 76
Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor
Rodríguez, D., Gao, Z.-G., Moss, S. M., Jacobson, K. A., & Carlsson, J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500639g · Cited by 71
RLDOCK: A New Method for Predicting RNA–Ligand Interactions
Sun, L., Jiang, Y., Zhou, Y., & Chen, S. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c00798 · Cited by 83
“3,4 Furthermore, RNA is critical to gene expression, 5 thus inhibiting RNA function may lead to the termination of the production of dozens or more proteins.”
BackgroundDiscovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors
Nataraja, S. G., Yu, H. N., & Palmer, S. S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00142 · Cited by 75
G protein‐coupled receptors participate in cytokinesis
Zhang, X., Bedigian, A. V., Wang, W., & Eggert, U. (2012) · Cytoskeleton · doi:10.1002/cm.21055 · Cited by 82
“It is estimated that the human genome has around 1000 GPCRs and they are one of the most studied target families in the pharmaceutical industry [Filmore, 2004; Overington et al., 2006; Gilchrist, 2010].”
BackgroundHall, S. C. L., Tognoloni, C., Price, G. J., Klumperman, B., Edler, K. J., Dafforn, T. R., & Arnold, T. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01539 · Cited by 72
Inducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 70
Song, T., Zhang, X., Ding, M., Rodríguez‐Patón, A., Wang, S., & Wang, G. (2022) · Methods · doi:10.1016/j.ymeth.2022.02.007 · Cited by 80
Yu, J., Li, H., Fang, T., Yun, C., Liu, X., Xu, J., Jiang, X., & Cai, X. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07687 · Cited by 73
Duan, Q., Jia, H., Chen, W., Qin, C., Zhang, K., Jia, F., Fu, T., Wei, Y., Fan, M., Wu, Q., et al. (2024) · Advanced Science · doi:10.1002/advs.202308924 · Cited by 79
Novel Therapeutic GPCRs for Psychiatric Disorders
Komatsu, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614109 · Cited by 82
“They govern numerous physiological responses including hemostasis, immune function, reproduction, cardiac function, metabolism, and neurotransmission [1].”
BackgroundAntisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects
Rigo, F., Seth, P. P., & Bennett, C. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-1221-6_9 · Cited by 80
Time-resolved fluorescence ligand binding for G protein–coupled receptors
Emami-Nemini, A., Roux, T., Leblay, M., Bourrier, E., Lamarque, L., Trinquet, E., & Lohse, M. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.073 · Cited by 85
Quantitative Prediction of Antitarget Interaction Profiles for Chemical Compounds
Zakharov, A. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. V. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300247r · Cited by 70
Direct Interaction between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4
Janz, J. M., Ren, Y., Looby, R. J., Kazmi, M. A., Sachdev, P., Grunbeck, A., Haggis, L., Chinnapen, D. J. ‐., Lin, A. Y. J., Seibert, C., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206661w · Cited by 71
Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening
Thaker, N. G., Zhang, F., McDonald, P. R., Shun, T. Y., Lewen, M. D., Pollack, I. F., & Lazo, J. S. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058024 · Cited by 73
“…which comprises siRNAs targeting gene products that are potential drug targets or are disease-modifying, such as ion channels, transporters, receptors, and protein kinases, to facilitate the target identification process (Hopkins and Groom, 2002; Russ and Lampel, 2005; Overington et al., 2006).”
BackgroundMethodPless, S. A., & Ahern, C. A. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140343 · Cited by 87
Colloidal Aggregation and the in Vitro Activity of Traditional Chinese Medicines
Duan, D., Doak, A. K., Nedyalkova, L., & Shoichet, B. K. (2015) · ACS Chemical Biology · doi:10.1021/cb5009487 · Cited by 77
A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors
Gundry, J., Glenn, R., Alagesan, P., & Rajagopal, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00017 · Cited by 72
“…smarter drugs that target GPCRs. Keywords: G protein coupled receptor, biased agonism, arrestins, G proteins, GRKs INTRODUCTION G protein-coupled receptors (GPCRs) are the most common receptors in the genome and one of the largest drug targets for neuroendocrine disease (Overington et al., 2006).”
BackgroundIngólfsson, H. I., Bhatia, H., Zeppelin, T., Bennett, W. F., Carpenter, K. A., Hsu, P., Dharuman, G., Bremer, P., Schiøtt, B., Lightstone, F. C., et al. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c03368 · Cited by 74
Snead, A. N., & Insel, P. A. (2012) · The FASEB Journal · doi:10.1096/fj.12-213496 · Cited by 81
“Since approaches to develop GPCR-targeted drugs are well established (6), validated GPCR targets might readily translate to new clinical therapies.”
BackgroundZhu, J., Sun, Z., Cheng, K., Chen, R., Ye, M., Xu, B., Sun, D., Wang, L., Liu, J., Wang, F., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr401200h · Cited by 70
Interferometric Methods for Label-Free Molecular Interaction Studies
Kussrow, A. K., Enders, C. S., & Bornhop, D. J. (2011) · Analytical Chemistry · doi:10.1021/ac202812h · Cited by 86
GPCR-ModSim: A comprehensive web based solution for modeling G-protein coupled receptors
Esguerra, M., Siretskiy, A., Bello, X., Sallander, J., & Gutiérrez-de-Terán, H. (2016) · Nucleic Acids Res. · doi:10.1093/nar/gkw403 · Cited by 68
“It is estimated that between 30 and 40% of marketed drugs target a GPCR (2), including many blockbusters in the pharmaceutical industry.”
BackgroundBosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
Carneiro, P. J., Clevelario, A. L., Padilha, G. A., Silva, J. D., Kitoko, J. Z., Olsen, P. C., Capelozzi, V. L., Rocco, P. R. M., & Cruz, F. F. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00159 · Cited by 74
“Because of its widespread involvement in numerous physiological and pathological processes (Thomas and Brugge, 1997; Dehm and Bonham, 2004; Lemmon and Schlessinger, 2010; Keller and Brummendorf, 2012), it is not surprising that the Src signaling pathway has been successfully targeted by multiple drug-discovery program…”
BackgroundThe In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Bruno, A., Costantino, G., Sartori, L., & Radi, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666171107101035 · Cited by 78
Predicting protein targets for drug-like compounds using transcriptomics
Pabon, N. A., Xia, Y., Estabrooks, S. K., Ye, Z., Herbrand, A. K., Süß, E., Biondi, R. M., Assimon, V. A., Gestwicki, J. E., Brodsky, J. L., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006651 · Cited by 79
“In principle, this is regularly done in cell-based phenotypic assays, but it is often unclear how to identify potential molecular targets in these experiments [9-11].”
BackgroundComputer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 82
Multiple tyrosine metabolites are GPR35 agonists
Deng, H., Hu, H., & Ye, F. (2012) · Scientific Reports · doi:10.1038/srep00373 · Cited by 77
“This work was motivated by (1) our recent discovery that certain tyrosine derivatives, tyrphostins including tyrphostin-51 and tyrphostin-25, are potent GPR35 agonists(14); (2) the fact that many of tyrosine metabolites including catecholamines have been long recognized to be native ligands of several families of GPCR…”
BackgroundOpen Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Roy, A., McDonald, P. R., Sittampalam, S., & Chaguturu, R. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110792927757 · Cited by 86
“05% of the human genome, a mere 106 genes and 378 targets [2].”
BackgroundGenetically Targeted Optical Control of an Endogenous G Protein-Coupled Receptor
Donthamsetti, P., Broichhagen, J., Vyklický, V., Stanley, C., Fu, Z., Visel, M., Levitz, J., Javitch, J. A., Trauner, D. H., & Isacoff, E. Y. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02895 · Cited by 72
Whole-cell imaging of plasma membrane receptors by 3D lattice light-sheet dSTORM
Wäldchen, F., Schlegel, J. A., Götz, R., Luciano, M., Schnermann, M. J., Doose, S., & Sauer, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14731-0 · Cited by 69
Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs
Roth, B. L. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0252-8 · Cited by 75
Gα i/o -coupled receptor signaling restricts pancreatic β-cell expansion
Berger, M., Scheel, D. W., Macias, H., Miyatsuka, T., Kim, H., Hoang, P., Ku, G. M., Honig, G., Liou, A., Tang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319378112 · Cited by 67
“T G protein-coupled receptors (GPCRs), including Gi-GPCRs (1), comprise the largest family of mammalian cell-surface receptors and the largest target group for Food and Drug Administration-approved drugs (2), including drugs used to treat diabetes (3).”
BackgroundImaging the distribution of polymyxins in the kidney
Yun, B., Azad, M. A. K., Wang, J., Nation, R. L., Thompson, P. E., Roberts, K. D., Velkov, T., & Li, J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku441 · Cited by 68
Schütz, M., Schöppe, J., Sedlák, E., Hillenbrand, M., Nagy‐Davidescu, G., Ehrenmann, J., Klenk, C., Egloff, P., Kummer, L., & Plückthun, A. (2016) · Scientific Reports · doi:10.1038/srep21508 · Cited by 76
Discovery of a ZIP7 inhibitor from a Notch pathway screen
Nolin, E., Gans, S., Llamas, L., Bandyopadhyay, S., Brittain, S. M., Bernasconi-Elias, P., Carter, K. P., Loureiro, J., Thomas, J. R., Schirle, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0200-7 · Cited by 70
Biological Relevance and Therapeutic Potential of the Hypusine Modification System
Pällmann, N., Braig, M., Sievert, H., Preukschas, M., Hermans‐Borgmeyer, I., Schweizer, M., Nagel, C., Neumann, M., Wild, P. J., Haralambieva, E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664490 · Cited by 71
“Together, a growing body of research now indicates that the enzymes of the hypusine system fulfill certain criteria for being a potential therapeutic target (25, 26), and consequently, lead substances have been developed (27, 28).”
BackgroundShowalter, H. D., & Denny, W. A. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70032-5 · Cited by 73
Boukharta, L., Gutiérrez‐de‐Terán, H., & Åqvist, J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003585 · Cited by 67
“They are targets for approximately 30% of all prescribed drugs and of major interest to the pharmaceutical industry [1].”
BackgroundHughes, M. L. R., Liu, B., Halls, M. L., Wagstaff, K. M., Patil, R., Velkov, T., Jans, D. A., Bunnett, N. W., Scanlon, M. J., & Porter, C. J. H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605998 · Cited by 67
“Approximately 13% of all Food and Drug Administrationapproved drugs interact with nuclear hormone receptors (NHRs)(6) (1).”
BackgroundBinding Kinetics and Pathways of Ligands to GPCRs
Straßer, A., Wittmann, H., & Seifert, R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.005 · Cited by 69
Menteşe, E., Yılmaz, F., Emirik, M., Ülker, S., & Kahveci, B. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.023 · Cited by 70
Site-Directed Spin Labeling EPR for Studying Membrane Proteins
Sahu, I. D., & Lorigan, G. A. (2018) · BioMed Research International · doi:10.1155/2018/3248289 · Cited by 78
Szlenk, C. T., GC, J. B., & Natesan, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.115113 · Cited by 71
“These integral membrane proteins are involved in many physiological and pathophysiological processes and continue to be the most privileged targets for approximately 33% of all small molecule drugs currently on the market (Overington et al., 2006; Santos et al., 2016).”
BackgroundPerspectives on the therapeutic potential of short-chain fatty acid receptors
Kim, S., Kim, J.-H., Park, B. O., & Kwak, Y. S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.272 · Cited by 65
“G-protein-coupled receptors (GPCRs) comprise a large family of seven-transmembrane receptors that convey various extracellular stimuli such as light, odorants, cytokines and hormones to a cascade of intracellular signaling.”
BackgroundInfluentialProteins: Sequence to Structure and Function – Current Status
Shenoy, S. R., & Jayaram, B. (2010) · Current Protein and Peptide Science · doi:10.2174/138920310794109094 · Cited by 74
“Their observation of phylogenetic reconstruction exercises, strongly suggested that metabolism originated in enzymes with the P-loop hydrolase fold in nucleotide metabolism, probably in pathways linked to the purine metabolic network [191].”
BackgroundLakkaraju, S. K., Yu, W., Raman, E. P., Hershfeld, A. V., Fang, L., Deshpande, D. A., & MacKerell, A. D. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500729k · Cited by 69
Binding Affinity Prediction for Protein–Ligand Complexes Based on β Contacts and B Factor
Liu, Q., Kwoh, C. K., & Li, J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400450h · Cited by 72
Rollins, D. A., Coppo, M., & Rogatsky, I. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1005 · Cited by 74
Insel, P. A., Wilderman, A. S., Zambon, A. C., Snead, A. N., Murray, F., Aroonsakool, N., McDonald, D., Zhou, S. M., McCann, T., Zhang, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098129 · Cited by 82
“%) of the targets of approved drugs (Overington et al., 2006; Lundstrom, 2009; Rask-Andersen et al., 2014).”
BackgroundSojo, V., Dessimoz, C., Pomiankowski, A., & Lane, N. (2016) · Molecular Biology and Evolution · doi:10.1093/molbev/msw164 · Cited by 69
“Over half of all known drug targets are membrane proteins (Overington et al. 2006).”
BackgroundHalogen Bonding in Nucleic Acid Complexes
Kolář, M. H., & Tabarrini, O. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00329 · Cited by 68
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 70
Ion channels as novel therapeutic targets in the treatment of pain
Mathie, A. A. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01131.x · Cited by 73
“Nevertheless, recent estimates suggest that existing drugs target just a few hundred proteins (or protein families), which corresponds to slightly over 1000 different human genes.([6]) The number of potential drug target proteins is, perhaps, an order of magnitude higher than this.”
BackgroundInfluentialNanoscale high-content analysis using compositional heterogeneities of single proteoliposomes
Mathiasen, S., Christensen, S. M., Fung, J. J., Rasmussen, S. G. F., Fay, J. F., Jørgensen, S. K., Veshaguri, S., Farrens, D., Kiskowski, M. A., Kobilka, B. K., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3062 · Cited by 66
Southan, C., Várkonyi, P., & Muresan, S. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-10 · Cited by 65
Flavonoids as dietary regulators of nuclear receptor activity
Avior, Y., Bomze, D., Ramon, O., & Nahmias, Y. (2013) · Food & Function · doi:10.1039/c3fo60063g · Cited by 77
Horner, R. L., Grace, K. P., & Wellman, A. (2017) · Respirology · doi:10.1111/resp.13079 · Cited by 63
Allostery in GPCRs: ‘MWC’ revisited
Canals, M., Sexton, P. M., & Christopoulos, A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.005 · Cited by 65
When simple agonism is not enough: Emerging modalities of GPCR ligands
Smith, N. J., Bennett, K. A., & Milligan, G. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.07.009 · Cited by 73
“…source of drug targets for the pharmaceutical industry, with blockbuster drugs acting at numerous GPCRs, most notably the monoaminergic (such as histamine, serotonin and the catecholamines) and angiotensin receptor families, constituting over 26% of all FDA-approved drugs (Overington et al., 2006).”
BackgroundNewton, C. L., Anderson, R. C., Katz, A. A., & Millar, R. P. (2016) · Endocrinology · doi:10.1210/en.2016-1104 · Cited by 65
“The central role of GPCR signaling in most human physiological processes is reflected by the number of pathophysiological conditions caused by impaired GPCR signal transduction, and also the large number of therapeutics targeting GPCR signaling pathways [approximately 30% of all marketed drugs (5)].”
BackgroundPredicting Drug-Target Interactions Over Heterogeneous Information Network
Su, X., Hu, P., Yi, H.-C., You, Z., & Hu, L. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3219213 · Cited by 70
“Previous studies have reported that there are approximately 6000-8000 targets of pharmacological interest existed in the human genome [2], [3].”
BackgroundDonthamsetti, P., Quejada, J. R., Javitch, J. A., Gurevich, V. V., & Lambert, N. A. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0214s70 · Cited by 64
“Bioluminescence resonance energy transfer (BRET), a technique used to measure proteinprotein interactions in living cells (Hamdan et al., 2006; Pfleger et al., 2006; Kocan and Pfleger, 2011; Salahpour et al., 2012), has been used to dynamically monitor arrestin recruitment to GPCRs.”
MethodComputational Models Reduce Complexity and Accelerate Insight Into Cardiac Signaling Networks
Yang, J. H., & Saucerman, J. J. (2011) · Circulation Research · doi:10.1161/circresaha.110.223602 · Cited by 68
“…Iyengar pioneered the use of large signaling network models, integrating many signaling pathways such as protein kinase (PK)A, PKC, mitogen-activated protein kinase, inositol 1,4,5-triphosphate (IP3), Ca 2 (cid:1) /calmodulin-dependent protein kinase (CaMK)II, and Ca 2 (cid:1) signaling in neurons.”
BackgroundChien, H.-C., Zur, A. A., Maurer, T. S., Yee, S. W., Tolsma, J., Jasper, P., Scott, D. O., & Giacomini, K. M. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066647 · Cited by 63
“Intracellular unbound drug concentrations are critical determinants of drug interactions with targets and enzymes because most drug metabolizing enzymes and drug targets are located inside cells (Overington et al., 2006; Dollery, 2013).”
BackgroundPharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors
Conn, P. M., & Ulloa‐Aguirre, A. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00008-7 · Cited by 64
Kramer, W. (2011) · Biological Chemistry · doi:10.1515/bc.2011.017 · Cited by 64
Dastvan, R., Bode, B. E., Karuppiah, M. P. R., Marko, A., Lyubenova, S., Schwalbe, H., & Prisner, T. F. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp1060039 · Cited by 63
The principle of conformational signaling
Tompa, P. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00011h · Cited by 67
Identification and pharmacological characterization of succinate receptor agonists
Geubelle, P., Gilissen, J., Dilly, S., Poma, L., Dupuis, N., Laschet, C., Abboud, D., Inoue, A., Jouret, F., Pirotte, B., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13738 · Cited by 68
“The GPCRs constitute the most broadly targeted proteins by drugs in human medicine (Overington et al., 2006).”
BackgroundThe fine art of integral membrane protein crystallisation
Birch, J., Axford, D., Foadi, J., Meyer, A., Eckhardt, A., Thielmann, Y., & Moraes, I. (2018) · Methods · doi:10.1016/j.ymeth.2018.05.014 · Cited by 63
Gαi/o-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later
Brust, T. F., Conley, J. M., & Watts, V. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.014 · Cited by 70
“Because of their diversity and prominent physiological relevance, GPCRs represent the most targeted class of proteins by FDA-approved drugs (Overington et al., 2006; Rask-Andersen et al., 2011).”
BackgroundSimulation of lipid bilayer self-assembly using all-atom lipid force fields
Skjevik, Å. A., Madej, B. D., Dickson, C. J., Lin, C. H., Teigen, K., Walker, R. C., & Gould, I. R. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp07379k · Cited by 69
Targeting Gpr52 lowers mutant HTT levels and rescues Huntington’s disease-associated phenotypes
Song, H., Li, H., Guo, S., Pan, Y., Fu, Y., Zhou, Z., Li, Z., Wen, X., Sun, X., He, B., et al. (2018) · Brain · doi:10.1093/brain/awy081 · Cited by 61
“G protein-coupled receptors (GPCRs) constitute the largest drug target family of FDA-approved drugs (Overington et al. , 2006).”
BackgroundDevelopment of Fish Parasite Vaccines in the OMICs Era: Progress and Opportunities
Shivam, S., El‐Matbouli, M., & Kumar, G. (2021) · Vaccines · doi:10.3390/vaccines9020179 · Cited by 62
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.